1. Home
  2. EOLS vs RPAY Comparison

EOLS vs RPAY Comparison

Compare EOLS & RPAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EOLS
  • RPAY
  • Stock Information
  • Founded
  • EOLS 2012
  • RPAY 2006
  • Country
  • EOLS United States
  • RPAY United States
  • Employees
  • EOLS N/A
  • RPAY N/A
  • Industry
  • EOLS Biotechnology: Pharmaceutical Preparations
  • RPAY Business Services
  • Sector
  • EOLS Health Care
  • RPAY Consumer Discretionary
  • Exchange
  • EOLS Nasdaq
  • RPAY Nasdaq
  • Market Cap
  • EOLS 493.5M
  • RPAY 473.8M
  • IPO Year
  • EOLS 2018
  • RPAY N/A
  • Fundamental
  • Price
  • EOLS $7.19
  • RPAY $5.89
  • Analyst Decision
  • EOLS Strong Buy
  • RPAY Buy
  • Analyst Count
  • EOLS 5
  • RPAY 9
  • Target Price
  • EOLS $21.25
  • RPAY $7.22
  • AVG Volume (30 Days)
  • EOLS 899.1K
  • RPAY 740.2K
  • Earning Date
  • EOLS 11-05-2025
  • RPAY 11-11-2025
  • Dividend Yield
  • EOLS N/A
  • RPAY N/A
  • EPS Growth
  • EOLS N/A
  • RPAY N/A
  • EPS
  • EOLS N/A
  • RPAY N/A
  • Revenue
  • EOLS $277,941,000.00
  • RPAY $310,367,000.00
  • Revenue This Year
  • EOLS $14.01
  • RPAY N/A
  • Revenue Next Year
  • EOLS $29.46
  • RPAY $9.47
  • P/E Ratio
  • EOLS N/A
  • RPAY N/A
  • Revenue Growth
  • EOLS 17.15
  • RPAY 1.45
  • 52 Week Low
  • EOLS $5.71
  • RPAY $3.59
  • 52 Week High
  • EOLS $17.82
  • RPAY $9.75
  • Technical
  • Relative Strength Index (RSI)
  • EOLS 42.33
  • RPAY 58.10
  • Support Level
  • EOLS $7.19
  • RPAY $5.62
  • Resistance Level
  • EOLS $7.75
  • RPAY $6.00
  • Average True Range (ATR)
  • EOLS 0.31
  • RPAY 0.20
  • MACD
  • EOLS 0.05
  • RPAY -0.01
  • Stochastic Oscillator
  • EOLS 0.65
  • RPAY 69.16

About EOLS Evolus Inc.

Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.

About RPAY Repay Holdings Corporation

Repay Holdings Corp is engaged in providing integrated payment processing solutions to verticals that have transaction processing needs. It allows customers to pay through Mobile App, Text, Interactive Voice Response, Virtual Terminal, Hosted Payment Page and Online Customer Portal among others. It operates in two segments Consumer Payments and Business Payments.

Share on Social Networks: